Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy
Authorized Users Only
2016
Authors
Ilić, VBogićević, Dragana
Miljković, Branislava

Ješić, M
Kovačević, M
Prostran, Milica

Vezmar-Kovačević, Sandra

Article (Published version)

Metadata
Show full item recordAbstract
Aim. To identify potential risk factors for the development of subclinical hypothyroidism following long-term valproic acid monotherapy in children with epilepsy. Methods. Serumlevels of thyroid-stimulating hormone, free thyroxine, free triiodothyronine, thyreoglobulin antibodies, and thyroid peroxidase antibodies were determined in 41 patients and in 41 sex- And age-matched healthy children. Results. Meanvalproic acid treatment durationwas 2.80?}1.96 years. The valproic acid group had higher serum thyroid-stimulating hormone (p lt 0.001) and free triiodothyronine (p lt 0.05) levels compared to the control group. Serum thyroid-stimulating hormone and free triiodothyronine were above the upper limit for healthy controls in 34% and 32% of patients, respectively, and no clinical features of thyroid dysfunction were observed. Duration of valproic acid monotherapy for less than four years was a risk factor for elevated thyroid-stimulating hormone levels. Conclusion. One third of children wi...th normal range serum valproic acid levels may have elevated serum thyroid-stimulating hormone and free triiodothyronine levels, especially in the first four years of treatment.
Keywords:
Children / Epilepsy / Thyroid function / Valproic acidSource:
Epileptic Disorders, 2016, 18, 2, 181-186Publisher:
- John Libbey Eurotext
Funding / projects:
Collections
Institution/Community
PharmacyTY - JOUR AU - Ilić, V AU - Bogićević, Dragana AU - Miljković, Branislava AU - Ješić, M AU - Kovačević, M AU - Prostran, Milica AU - Vezmar-Kovačević, Sandra PY - 2016 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2767 AB - Aim. To identify potential risk factors for the development of subclinical hypothyroidism following long-term valproic acid monotherapy in children with epilepsy. Methods. Serumlevels of thyroid-stimulating hormone, free thyroxine, free triiodothyronine, thyreoglobulin antibodies, and thyroid peroxidase antibodies were determined in 41 patients and in 41 sex- And age-matched healthy children. Results. Meanvalproic acid treatment durationwas 2.80?}1.96 years. The valproic acid group had higher serum thyroid-stimulating hormone (p lt 0.001) and free triiodothyronine (p lt 0.05) levels compared to the control group. Serum thyroid-stimulating hormone and free triiodothyronine were above the upper limit for healthy controls in 34% and 32% of patients, respectively, and no clinical features of thyroid dysfunction were observed. Duration of valproic acid monotherapy for less than four years was a risk factor for elevated thyroid-stimulating hormone levels. Conclusion. One third of children with normal range serum valproic acid levels may have elevated serum thyroid-stimulating hormone and free triiodothyronine levels, especially in the first four years of treatment. PB - John Libbey Eurotext T2 - Epileptic Disorders T1 - Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy VL - 18 IS - 2 SP - 181 EP - 186 DO - 10.1684/epd.2016.0821 ER -
@article{ author = "Ilić, V and Bogićević, Dragana and Miljković, Branislava and Ješić, M and Kovačević, M and Prostran, Milica and Vezmar-Kovačević, Sandra", year = "2016", abstract = "Aim. To identify potential risk factors for the development of subclinical hypothyroidism following long-term valproic acid monotherapy in children with epilepsy. Methods. Serumlevels of thyroid-stimulating hormone, free thyroxine, free triiodothyronine, thyreoglobulin antibodies, and thyroid peroxidase antibodies were determined in 41 patients and in 41 sex- And age-matched healthy children. Results. Meanvalproic acid treatment durationwas 2.80?}1.96 years. The valproic acid group had higher serum thyroid-stimulating hormone (p lt 0.001) and free triiodothyronine (p lt 0.05) levels compared to the control group. Serum thyroid-stimulating hormone and free triiodothyronine were above the upper limit for healthy controls in 34% and 32% of patients, respectively, and no clinical features of thyroid dysfunction were observed. Duration of valproic acid monotherapy for less than four years was a risk factor for elevated thyroid-stimulating hormone levels. Conclusion. One third of children with normal range serum valproic acid levels may have elevated serum thyroid-stimulating hormone and free triiodothyronine levels, especially in the first four years of treatment.", publisher = "John Libbey Eurotext", journal = "Epileptic Disorders", title = "Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy", volume = "18", number = "2", pages = "181-186", doi = "10.1684/epd.2016.0821" }
Ilić, V., Bogićević, D., Miljković, B., Ješić, M., Kovačević, M., Prostran, M.,& Vezmar-Kovačević, S.. (2016). Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy. in Epileptic Disorders John Libbey Eurotext., 18(2), 181-186. https://doi.org/10.1684/epd.2016.0821
Ilić V, Bogićević D, Miljković B, Ješić M, Kovačević M, Prostran M, Vezmar-Kovačević S. Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy. in Epileptic Disorders. 2016;18(2):181-186. doi:10.1684/epd.2016.0821 .
Ilić, V, Bogićević, Dragana, Miljković, Branislava, Ješić, M, Kovačević, M, Prostran, Milica, Vezmar-Kovačević, Sandra, "Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy" in Epileptic Disorders, 18, no. 2 (2016):181-186, https://doi.org/10.1684/epd.2016.0821 . .